Amphetamine-induced striatal dopamine release in schizotypal personality disorder

Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacology 2020-09, Vol.237 (9), p.2649-2659
Hauptverfasser: Thompson, Judy L., Rosell, Daniel R., Slifstein, Mark, Xu, Xiaoyan, Rothstein, Ethan G., Modiano, Yosefa A., Kegeles, Lawrence S., Koenigsberg, Harold W., New, Antonia S., Hazlett, Erin A., McClure, Margaret M., Perez-Rodriguez, M. Mercedes, Siever, Larry J., Abi-Dargham, Anissa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2659
container_issue 9
container_start_page 2649
container_title Psychopharmacology
container_volume 237
creator Thompson, Judy L.
Rosell, Daniel R.
Slifstein, Mark
Xu, Xiaoyan
Rothstein, Ethan G.
Modiano, Yosefa A.
Kegeles, Lawrence S.
Koenigsberg, Harold W.
New, Antonia S.
Hazlett, Erin A.
McClure, Margaret M.
Perez-Rodriguez, M. Mercedes
Siever, Larry J.
Abi-Dargham, Anissa
description Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [ 11 C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP ND ), and its percent change post-amphetamine (∆BP ND ) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BP ND or ∆BP ND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP ND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP ND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
doi_str_mv 10.1007/s00213-020-05561-5
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2416272826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A635911686</galeid><sourcerecordid>A635911686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</originalsourceid><addsrcrecordid>eNp9kU9L5TAUxYOM6Bv1C7iQghs30fxvunyIOgOCCLoOaXqrkbapSbt48-kn7z1HUWSSRSD3dw73cBA6puScElJeJEIY5ZgwgomUimK5gxZUcIYZKdkPtCCEc8yp1PvoZ0ovJB-hxR7a50yWTGq9QPfLfnyGyfZ-AOyHZnbQFGmK3k62K5owbiZFhA5sgsIPRXLP_k-YVmOejxBTGGznp1XR-BRiA_EQ7ba2S3D09h6gx-urh8tf-Pbu5vfl8hY7IdiEeSWE42XtnOK81rRUjoKS0oK0DEpp67JWda0JUC1EBczRHJSpDLYOKsEP0NnWd4zhdYY0md4nB11nBwhzMkxQxUqmmcro6Rf0Jcwx750pqYSqNFfig3qyHRg_tGGK1q1NzVJxWVGq9Nrr_Bsq3wZ678IArc__nwRsK3AxpBShNWP0vY0rQ4lZ92i2PZocz2x6NDKLTt42nusemnfJv-IywLdAyqPhCeJHpP_Y_gWUwKZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564698364</pqid></control><display><type>article</type><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</creator><creatorcontrib>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</creatorcontrib><description>Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [ 11 C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP ND ), and its percent change post-amphetamine (∆BP ND ) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BP ND or ∆BP ND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP ND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP ND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-020-05561-5</identifier><identifier>PMID: 32572588</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Amphetamine - pharmacology ; Amphetamines ; Biomedical and Life Sciences ; Biomedicine ; Brain research ; Cognitive ability ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Dopamine ; Dopamine - metabolism ; Dopamine D2 receptors ; Dopamine Uptake Inhibitors - pharmacology ; Female ; Humans ; Male ; Medical colleges ; Memory, Short-Term - drug effects ; Memory, Short-Term - physiology ; Mental disorders ; Middle Aged ; Neostriatum ; Neurosciences ; Original Investigation ; Personality ; Personality disorders ; PET imaging ; Pharmacology/Toxicology ; Phenols ; Positron emission tomography ; Positron-Emission Tomography - methods ; Psychiatry ; Raclopride ; Receptors, Dopamine D2 - metabolism ; Schizophrenia ; Schizotypal personality disorder ; Schizotypal Personality Disorder - diagnostic imaging ; Schizotypal Personality Disorder - metabolism ; Schizotypal Personality Disorder - psychology ; Short term memory ; Young Adult</subject><ispartof>Psychopharmacology, 2020-09, Vol.237 (9), p.2649-2659</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</citedby><cites>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</cites><orcidid>0000-0001-8964-4934</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-020-05561-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-020-05561-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32572588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Judy L.</creatorcontrib><creatorcontrib>Rosell, Daniel R.</creatorcontrib><creatorcontrib>Slifstein, Mark</creatorcontrib><creatorcontrib>Xu, Xiaoyan</creatorcontrib><creatorcontrib>Rothstein, Ethan G.</creatorcontrib><creatorcontrib>Modiano, Yosefa A.</creatorcontrib><creatorcontrib>Kegeles, Lawrence S.</creatorcontrib><creatorcontrib>Koenigsberg, Harold W.</creatorcontrib><creatorcontrib>New, Antonia S.</creatorcontrib><creatorcontrib>Hazlett, Erin A.</creatorcontrib><creatorcontrib>McClure, Margaret M.</creatorcontrib><creatorcontrib>Perez-Rodriguez, M. Mercedes</creatorcontrib><creatorcontrib>Siever, Larry J.</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [ 11 C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP ND ), and its percent change post-amphetamine (∆BP ND ) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BP ND or ∆BP ND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP ND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP ND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Amphetamine - pharmacology</subject><subject>Amphetamines</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain research</subject><subject>Cognitive ability</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine D2 receptors</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical colleges</subject><subject>Memory, Short-Term - drug effects</subject><subject>Memory, Short-Term - physiology</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Neostriatum</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Personality</subject><subject>Personality disorders</subject><subject>PET imaging</subject><subject>Pharmacology/Toxicology</subject><subject>Phenols</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Psychiatry</subject><subject>Raclopride</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>Schizophrenia</subject><subject>Schizotypal personality disorder</subject><subject>Schizotypal Personality Disorder - diagnostic imaging</subject><subject>Schizotypal Personality Disorder - metabolism</subject><subject>Schizotypal Personality Disorder - psychology</subject><subject>Short term memory</subject><subject>Young Adult</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9L5TAUxYOM6Bv1C7iQghs30fxvunyIOgOCCLoOaXqrkbapSbt48-kn7z1HUWSSRSD3dw73cBA6puScElJeJEIY5ZgwgomUimK5gxZUcIYZKdkPtCCEc8yp1PvoZ0ovJB-hxR7a50yWTGq9QPfLfnyGyfZ-AOyHZnbQFGmK3k62K5owbiZFhA5sgsIPRXLP_k-YVmOejxBTGGznp1XR-BRiA_EQ7ba2S3D09h6gx-urh8tf-Pbu5vfl8hY7IdiEeSWE42XtnOK81rRUjoKS0oK0DEpp67JWda0JUC1EBczRHJSpDLYOKsEP0NnWd4zhdYY0md4nB11nBwhzMkxQxUqmmcro6Rf0Jcwx750pqYSqNFfig3qyHRg_tGGK1q1NzVJxWVGq9Nrr_Bsq3wZ678IArc__nwRsK3AxpBShNWP0vY0rQ4lZ92i2PZocz2x6NDKLTt42nusemnfJv-IywLdAyqPhCeJHpP_Y_gWUwKZs</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Thompson, Judy L.</creator><creator>Rosell, Daniel R.</creator><creator>Slifstein, Mark</creator><creator>Xu, Xiaoyan</creator><creator>Rothstein, Ethan G.</creator><creator>Modiano, Yosefa A.</creator><creator>Kegeles, Lawrence S.</creator><creator>Koenigsberg, Harold W.</creator><creator>New, Antonia S.</creator><creator>Hazlett, Erin A.</creator><creator>McClure, Margaret M.</creator><creator>Perez-Rodriguez, M. Mercedes</creator><creator>Siever, Larry J.</creator><creator>Abi-Dargham, Anissa</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8964-4934</orcidid></search><sort><creationdate>20200901</creationdate><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><author>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Amphetamine - pharmacology</topic><topic>Amphetamines</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain research</topic><topic>Cognitive ability</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine D2 receptors</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical colleges</topic><topic>Memory, Short-Term - drug effects</topic><topic>Memory, Short-Term - physiology</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Neostriatum</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Personality</topic><topic>Personality disorders</topic><topic>PET imaging</topic><topic>Pharmacology/Toxicology</topic><topic>Phenols</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Psychiatry</topic><topic>Raclopride</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>Schizophrenia</topic><topic>Schizotypal personality disorder</topic><topic>Schizotypal Personality Disorder - diagnostic imaging</topic><topic>Schizotypal Personality Disorder - metabolism</topic><topic>Schizotypal Personality Disorder - psychology</topic><topic>Short term memory</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Judy L.</creatorcontrib><creatorcontrib>Rosell, Daniel R.</creatorcontrib><creatorcontrib>Slifstein, Mark</creatorcontrib><creatorcontrib>Xu, Xiaoyan</creatorcontrib><creatorcontrib>Rothstein, Ethan G.</creatorcontrib><creatorcontrib>Modiano, Yosefa A.</creatorcontrib><creatorcontrib>Kegeles, Lawrence S.</creatorcontrib><creatorcontrib>Koenigsberg, Harold W.</creatorcontrib><creatorcontrib>New, Antonia S.</creatorcontrib><creatorcontrib>Hazlett, Erin A.</creatorcontrib><creatorcontrib>McClure, Margaret M.</creatorcontrib><creatorcontrib>Perez-Rodriguez, M. Mercedes</creatorcontrib><creatorcontrib>Siever, Larry J.</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Judy L.</au><au>Rosell, Daniel R.</au><au>Slifstein, Mark</au><au>Xu, Xiaoyan</au><au>Rothstein, Ethan G.</au><au>Modiano, Yosefa A.</au><au>Kegeles, Lawrence S.</au><au>Koenigsberg, Harold W.</au><au>New, Antonia S.</au><au>Hazlett, Erin A.</au><au>McClure, Margaret M.</au><au>Perez-Rodriguez, M. Mercedes</au><au>Siever, Larry J.</au><au>Abi-Dargham, Anissa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>237</volume><issue>9</issue><spage>2649</spage><epage>2659</epage><pages>2649-2659</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [ 11 C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP ND ), and its percent change post-amphetamine (∆BP ND ) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BP ND or ∆BP ND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP ND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP ND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32572588</pmid><doi>10.1007/s00213-020-05561-5</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8964-4934</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacology, 2020-09, Vol.237 (9), p.2649-2659
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_2416272826
source MEDLINE; SpringerLink Journals
subjects Adolescent
Adult
Amphetamine - pharmacology
Amphetamines
Biomedical and Life Sciences
Biomedicine
Brain research
Cognitive ability
Corpus Striatum - diagnostic imaging
Corpus Striatum - drug effects
Corpus Striatum - metabolism
Dopamine
Dopamine - metabolism
Dopamine D2 receptors
Dopamine Uptake Inhibitors - pharmacology
Female
Humans
Male
Medical colleges
Memory, Short-Term - drug effects
Memory, Short-Term - physiology
Mental disorders
Middle Aged
Neostriatum
Neurosciences
Original Investigation
Personality
Personality disorders
PET imaging
Pharmacology/Toxicology
Phenols
Positron emission tomography
Positron-Emission Tomography - methods
Psychiatry
Raclopride
Receptors, Dopamine D2 - metabolism
Schizophrenia
Schizotypal personality disorder
Schizotypal Personality Disorder - diagnostic imaging
Schizotypal Personality Disorder - metabolism
Schizotypal Personality Disorder - psychology
Short term memory
Young Adult
title Amphetamine-induced striatal dopamine release in schizotypal personality disorder
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T02%3A58%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amphetamine-induced%20striatal%20dopamine%20release%20in%20schizotypal%20personality%20disorder&rft.jtitle=Psychopharmacology&rft.au=Thompson,%20Judy%20L.&rft.date=2020-09-01&rft.volume=237&rft.issue=9&rft.spage=2649&rft.epage=2659&rft.pages=2649-2659&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-020-05561-5&rft_dat=%3Cgale_proqu%3EA635911686%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564698364&rft_id=info:pmid/32572588&rft_galeid=A635911686&rfr_iscdi=true